GlassScriptPhysician profile
Vu M Mai
NPI 1497086755
$8,744.72
in general payments reported to CMS, 2019-2025
35 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $1,345 · 2021: $1,296 · 2022: $1,139 · 2023: $1,103 · 2024: $1,190 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,557.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,496.02 | 2019-2025 | |
| Lilly USA, LLC | $1,129.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $886.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $660.10 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $625.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $492.12 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $410.93 | 2022-2025 | |
| Novo Nordisk INC | $386.81 | 2020-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $310.66 | 2019-2024 | |
| Gilead Sciences, INC. | $298.51 | 2019-2025 | |
| Astellas Pharma US INC | $226.99 | 2020-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.90 | 2023-2025 | Caplyta |
| Amgen INC. | $205.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.25 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $125.16 | 2024-2025 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $113.36 | 2019 | |
| Vanda Pharmaceuticals INC. | $109.53 | 2025 | Fanapt |
| Scilex Pharmaceuticals INC. | $100.55 | 2024-2025 | |
| Orexo US, INC. | $92.02 | 2019-2025 | Zubsolv |
| Novartis Pharmaceuticals Corporation | $86.99 | 2019-2023 | |
| Exact Sciences Corporation | $78.24 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $68.57 | 2023-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $64.67 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $64.13 | 2020-2021 | |
| Corcept Therapeutics | $58.91 | 2025 | Korlym |
| Ardelyx, INC. | $44.98 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $37.43 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $34.88 | 2021 | |
| Abbott Laboratories | $24.87 | 2023 | Freestyle Libre |
| Azurity Pharmaceuticals, INC. | $23.04 | 2023 | Edarbi |
| Braeburn INC. | $17.30 | 2023 | Brixadi |
| Lundbeck LLC | $17.11 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $14.80 | 2023 | Quviviq |
| Genentech USA, INC. | $14.55 | 2019 | |
| Aimmune Therapeutics, INC. | $14.03 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.